Cetera Advisors
FTXH icon

Cetera Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Cetera Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,053
Closed -$550K – 1677
2022
Q4 		$550K Buy
+20,053
New +$534K 0.01% 927

Other funds holding FTXH

Raymond James Financial Services Advisors
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Steward Partners Investment Advisory
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
WFA
WMG Financial Advisors Knoxville, Tennessee $265M AUM 16.66% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Nilsine Partners
Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Kesler Norman & Wride
Kesler Norman & Wride Ogden, Utah $643M AUM 27% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Paragon Private Wealth Management
Paragon Private Wealth Management Lexington, Kentucky $326M AUM 26.55% 1-Year Est. Return

Cetera Advisors's FTXH Position: Q1 2023 in Review

Cetera Advisors sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2023, closing a stake of 20,053 shares — an estimated $550K sold.

Cetera Advisors first reported a position in FTXH in Q4 2022 and held it in 1 quarter. The position peaked at $550K in Q4 2022. 31 funds tracked by Wall St. Rank hold FTXH as of Q1 2023.

  • Cetera Advisors reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
  • Cetera Advisors sold 20,053 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2023, an estimated $550K.
  • Cetera Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 1 quarter.
  • Cetera Advisors's First Trust Nasdaq Pharmaceuticals ETF position peaked at $550K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2023.

Based on Cetera Advisors's 13F filing for Q1 2023, filed 15 May 2023.